November 15, 2016
This post originally appeared in the Liverpool School of Tropical Medicine
The LSTM based A-WOL consortium discovered the molecule TylAMac™ , which has been selected as a candidate for development as the first drug designed for the curative treatment of onchocerciasis and lymphatic filariasis.
LSTM Professors Mark Taylor and Steve Ward are meeting with collaborators from Abbvie and Drugs for Neglected Diseases initiative (DNDi) to discuss the progress of the newly candidate at the Annual Meeting of the American Society of Tropical Medicine & Hygiene (ASTMH) in Atlanta, USA.
The discovery represents many firsts: it is the first new candidate drug to emerge from the Bill and Melinda Gates Foundation funded A-WOL consortium; the first drug ever designed specifically for onchocerciasis (river blindness) and lymphatic filariasis (elephantiasis); and the first drug designed to deliver a macrofilaricide action (killing of adult parasites) by eliminating the mutualistic endosymbiont Wolbachia from the parasite.
This milestone marks the culmination of almost a decade of research by the A-WOL consortium to identify new macrofilaricide drugs. LSTM’s Deputy Director, Professor Steve Ward said: “The achievement of candidate selection with TylAMac™ demonstrates the power of product development partnerships, in this case A-WOL, Abbvie and DNDi, in delivering efficient and relevant drug discovery projects for Neglected Tropical Diseases (NTDs) that are innovative and meet international regulatory standards.”